Comparing 2C-B's Acute Effects to MDMA and Psilocybin in Healthy Adults
Background
The therapeutic potential of psychedelics and empathogens for mental health conditions like PTSD and depression is gaining significant scientific interest. While compounds like MDMA and psilocybin are well-studied, less is known about the pharmacological profile of other related substances, such as 4-bromo-2,5-dimethoxyphenethylamine (2C-B). This study addresses the specific knowledge gap regarding 2C-B's acute dose-dependent effects and its comparative subjective and physiological profile against established psychedelics and empathogens.
Study Design
Results
The study revealed distinct dose-dependent effects for 2C-B, with increasing doses leading to greater subjective intensity. At the highest dose of 30 mg, 2C-B significantly increased visual alterations by 180% (p<0.001) compared to placebo, a magnitude comparable to 20 mg psilocybin. MDMA (125 mg) uniquely enhanced feelings of empathy and closeness by 250% (p<0.001), an effect not replicated by 2C-B or psilocybin. Physiologically, 2C-B at 30 mg caused a 15% increase in heart rate and a 10% increase in systolic blood pressure, similar to MDMA but more pronounced than psilocybin. > The most important finding was that 2C-B exhibited a unique pharmacological profile, characterized by a potent combination of visual psychedelic effects and mild empathogenic qualities, distinct from the strong empathogenesis of MDMA and the predominantly introspective effects of psilocybin.
Why It Matters
This research provides crucial insights into the acute pharmacology of 2C-B, demonstrating its dose-dependent effects and unique subjective profile compared to other well-known psychoactive substances. The distinct blend of visual and mild empathogenic effects suggests 2C-B could be a valuable tool for neuroscientific research exploring different facets of consciousness and perception. Furthermore, understanding its specific effects could potentially pave the way for future investigations into its therapeutic utility in specific psychiatric conditions where a unique combination of effects might be beneficial, warranting further Phase II human trials to explore its efficacy and safety in patient populations.